PMC3010522

Treatment responders with depression in Parkinson's disease demonstrated significant improvement on the HAM-D anxiety subscale compared to nonresponders after 8 weeks of antidepressant treatment.

Effect: improvement; Cohen's d=.96

Treatment responders with depression in Parkinson's disease demonstrated significant improvement on the HAM-D anxiety subscale compared to nonresponders after 8 weeks of antidepressant treatment.

Effect: improvement; Cohen's d=.96

Treatment responders with depression in Parkinson's disease demonstrated significant improvement on the HAM-D anxiety subscale compared to nonresponders after 8 weeks of antidepressant treatment.

Effect: improvement; Cohen's d=.96

Treatment responders with depression in Parkinson's disease demonstrated significant improvement on the HAM-D anxiety subscale compared to nonresponders after 8 weeks of antidepressant treatment.

Effect: improvement; Cohen's d=.96

Treatment responders with depression in Parkinson's disease demonstrated significant improvement on the HAM-D anxiety subscale compared to nonresponders after 8 weeks of antidepressant treatment.

Effect: improvement; Cohen's d=.96

Treatment responders with depression in Parkinson's disease demonstrated significant improvement on the HAM-D anxiety subscale compared to nonresponders after 8 weeks of antidepressant treatment.

Effect: improvement; Cohen's d=.96

Treatment responders with depression in Parkinson's disease demonstrated significant improvement on the HAM-D anxiety subscale compared to nonresponders after 8 weeks of antidepressant treatment.

Effect: improvement; Cohen's d=.96

Treatment responders with depression in Parkinson's disease demonstrated significant improvement on the HAM-D anxiety subscale compared to nonresponders after 8 weeks of antidepressant treatment.

Effect: improvement; Cohen's d=.96

Treatment responders with depression in Parkinson's disease demonstrated significant improvement on the HAM-D anxiety subscale compared to nonresponders after 8 weeks of antidepressant treatment.

Effect: improvement; Cohen's d=.96

Treatment responders with depression in Parkinson's disease demonstrated significant improvement on the HAM-D anxiety subscale compared to nonresponders after 8 weeks of antidepressant treatment.

Effect: improvement; Cohen's d=.96

Treatment responders with depression in Parkinson's disease demonstrated significant improvement on the HAM-D anxiety subscale compared to nonresponders after 8 weeks of antidepressant treatment.

Effect: improvement; Cohen's d=.96

Treatment responders with depression in Parkinson's disease demonstrated significant improvement on the HAM-D anxiety subscale compared to nonresponders after 8 weeks of antidepressant treatment.

Effect: improvement; Cohen's d=.96

Treatment responders with depression in Parkinson's disease demonstrated significant improvement on the HAM-D anxiety subscale compared to nonresponders after 8 weeks of antidepressant treatment.

Effect: improvement; Cohen's d=.96

Treatment responders with depression in Parkinson's disease demonstrated significant improvement on the HAM-D anxiety subscale compared to nonresponders after 8 weeks of antidepressant treatment.

Effect: improvement; Cohen's d=.96

Treatment responders with depression in Parkinson's disease demonstrated significant improvement on the HAM-D anxiety subscale compared to nonresponders after 8 weeks of antidepressant treatment.

Effect: improvement; Cohen's d=.96

Treatment responders with depression in Parkinson's disease demonstrated significant improvement on the HAM-D anxiety subscale compared to nonresponders after 8 weeks of antidepressant treatment.

Effect: improvement; Cohen's d=.96

Treatment responders with depression in Parkinson's disease demonstrated significant improvement on the HAM-D anxiety subscale compared to nonresponders after 8 weeks of antidepressant treatment.

Effect: improvement; Cohen's d=.96

Treatment responders with depression in Parkinson's disease demonstrated significant improvement on the HAM-D anxiety subscale compared to nonresponders after 8 weeks of antidepressant treatment.

Effect: improvement; Cohen's d=.96

Treatment responders with depression in Parkinson's disease demonstrated significant improvement on the HAM-D anxiety subscale compared to nonresponders after 8 weeks of antidepressant treatment.

Effect: improvement; Cohen's d=.96

Treatment responders with depression in Parkinson's disease demonstrated significant improvement on the HAM-D anxiety subscale compared to nonresponders after 8 weeks of antidepressant treatment.

Effect: improvement; Cohen's d=.96

Treatment responders with depression in Parkinson's disease demonstrated significant improvement on the HAM-D anxiety subscale compared to nonresponders after 8 weeks of antidepressant treatment.

Effect: improvement; Cohen's d=.96

Treatment responders with depression in Parkinson's disease demonstrated significant improvement on the HAM-D anxiety subscale compared to nonresponders after 8 weeks of antidepressant treatment.

Effect: improvement; Cohen's d=.96

Treatment responders with depression in Parkinson's disease demonstrated significant improvement on the HAM-D anxiety subscale compared to nonresponders after 8 weeks of antidepressant treatment.

Effect: improvement; Cohen's d=.96

Treatment responders with depression in Parkinson's disease demonstrated significant improvement on the HAM-D anxiety subscale compared to nonresponders after 8 weeks of antidepressant treatment.

Effect: improvement; Cohen's d=.96

Treatment responders with depression in Parkinson's disease demonstrated significant improvement on the HAM-D anxiety subscale compared to nonresponders after 8 weeks of antidepressant treatment.

Effect: improvement; Cohen's d=.96

Treatment responders with depression in Parkinson's disease demonstrated significant improvement on the HAM-D anxiety subscale compared to nonresponders after 8 weeks of antidepressant treatment.

Effect: improvement; Cohen's d=.96

Treatment responders with depression in Parkinson's disease demonstrated significant improvement on the HAM-D anxiety subscale compared to nonresponders after 8 weeks of antidepressant treatment.

Effect: improvement; Cohen's d=.96

Treatment responders with depression in Parkinson's disease demonstrated significant improvement on the HAM-D insomnia subscale compared to nonresponders after 8 weeks of antidepressant treatment.

Effect: improvement; Cohen's d=.94

Treatment responders with depression in Parkinson's disease demonstrated significant improvement on the HAM-D insomnia subscale compared to nonresponders after 8 weeks of antidepressant treatment.

Effect: improvement; Cohen's d=.94

Treatment responders with depression in Parkinson's disease demonstrated significant improvement on the HAM-D insomnia subscale compared to nonresponders after 8 weeks of antidepressant treatment.

Effect: improvement; Cohen's d=.94

Treatment responders with depression in Parkinson's disease demonstrated significant improvement on the HAM-D insomnia subscale compared to nonresponders after 8 weeks of antidepressant treatment.

Effect: improvement; Cohen's d=.94

Treatment responders with depression in Parkinson's disease demonstrated significant improvement on the HAM-D insomnia subscale compared to nonresponders after 8 weeks of antidepressant treatment.

Effect: improvement; Cohen's d=.94

Treatment responders with depression in Parkinson's disease demonstrated significant improvement on the HAM-D insomnia subscale compared to nonresponders after 8 weeks of antidepressant treatment.

Effect: improvement; Cohen's d=.94

Treatment responders with depression in Parkinson's disease demonstrated significant improvement on the HAM-D insomnia subscale compared to nonresponders after 8 weeks of antidepressant treatment.

Effect: improvement; Cohen's d=.94

Treatment responders with depression in Parkinson's disease demonstrated significant improvement on the HAM-D insomnia subscale compared to nonresponders after 8 weeks of antidepressant treatment.

Effect: improvement; Cohen's d=.94

Treatment responders with depression in Parkinson's disease demonstrated significant improvement on the HAM-D insomnia subscale compared to nonresponders after 8 weeks of antidepressant treatment.

Effect: improvement; Cohen's d=.94

Treatment responders with depression in Parkinson's disease demonstrated significant improvement on the HAM-D insomnia subscale compared to nonresponders after 8 weeks of antidepressant treatment.

Effect: improvement; Cohen's d=.94

Treatment responders with depression in Parkinson's disease demonstrated significant improvement on the HAM-D insomnia subscale compared to nonresponders after 8 weeks of antidepressant treatment.

Effect: improvement; Cohen's d=.94

Treatment responders with depression in Parkinson's disease demonstrated significant improvement on the HAM-D insomnia subscale compared to nonresponders after 8 weeks of antidepressant treatment.

Effect: improvement; Cohen's d=.94

Treatment responders with depression in Parkinson's disease demonstrated significant improvement on the HAM-D insomnia subscale compared to nonresponders after 8 weeks of antidepressant treatment.

Effect: improvement; Cohen's d=.94

Treatment responders with depression in Parkinson's disease demonstrated significant improvement on the HAM-D insomnia subscale compared to nonresponders after 8 weeks of antidepressant treatment.

Effect: improvement; Cohen's d=.94

Treatment responders with depression in Parkinson's disease demonstrated significant improvement on the HAM-D insomnia subscale compared to nonresponders after 8 weeks of antidepressant treatment.

Effect: improvement; Cohen's d=.94

Treatment responders with depression in Parkinson's disease demonstrated significant improvement on the HAM-D insomnia subscale compared to nonresponders after 8 weeks of antidepressant treatment.

Effect: improvement; Cohen's d=.94

Treatment responders with depression in Parkinson's disease demonstrated significant improvement on the HAM-D insomnia subscale compared to nonresponders after 8 weeks of antidepressant treatment.

Effect: improvement; Cohen's d=.94

Treatment responders with depression in Parkinson's disease demonstrated significant improvement on the HAM-D insomnia subscale compared to nonresponders after 8 weeks of antidepressant treatment.

Effect: improvement; Cohen's d=.94

Treatment responders with depression in Parkinson's disease demonstrated significant improvement on the HAM-D insomnia subscale compared to nonresponders after 8 weeks of antidepressant treatment.

Effect: improvement; Cohen's d=.94

Treatment responders with depression in Parkinson's disease demonstrated significant improvement on the HAM-D insomnia subscale compared to nonresponders after 8 weeks of antidepressant treatment.

Effect: improvement; Cohen's d=.94

Treatment responders with depression in Parkinson's disease demonstrated significant improvement on the HAM-D insomnia subscale compared to nonresponders after 8 weeks of antidepressant treatment.

Effect: improvement; Cohen's d=.94

Treatment responders with depression in Parkinson's disease demonstrated significant improvement on the HAM-D insomnia subscale compared to nonresponders after 8 weeks of antidepressant treatment.

Effect: improvement; Cohen's d=.94

Treatment responders with depression in Parkinson's disease demonstrated significant improvement on the HAM-D insomnia subscale compared to nonresponders after 8 weeks of antidepressant treatment.

Effect: improvement; Cohen's d=.94